[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632830":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":43,"centralContacts":47,"locations":56,"responsibleParty":75,"collaborators":78,"id":85,"slug":10,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":10,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":10,"enrollmentInfo":93,"targetDuration":10,"studyType":96,"phases":10,"briefSummary":97,"conditions":98,"keywords":10,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University of California, San Diego","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single arm",null,"This is a single arm study in which all participants undergo the same research procedures.",[13,14,15,16,17],"Diagnostic Test: LiverScope® exam","Diagnostic Test: MR exam","Diagnostic Test: Blood draw","Other: Body measurements","Other: Questionnaire",[19,24,31,35,39],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","LiverScope® exam","Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"MR exam","Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.",[9],[29,30],"MRI","MRI exam",{"type":20,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Blood draw","A blood sample of approximately 10 mL will be collected for routine laboratory tests including complete blood count (CBC) and comprehensive metabolic panel (CMP).",[9],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Body measurements","Height, weight, waist circumference, and hip circumference will be measured.",[9],{"type":6,"name":40,"description":41,"armGroupLabels":42,"otherNames":10},"Questionnaire","A questionnaire will be administered to collect demographic information (including age, sex, race, and ethnicity), and medical and social history (including alcohol use, tobacco use, history of diabetes, history of liver disease, and current medications).",[9],[44],{"name":45,"affiliation":5,"role":46},"Claude B Sirlin, MD","PRINCIPAL_INVESTIGATOR",[48,53],{"name":49,"role":50,"phone":51,"phoneExt":10,"email":52},"Yesenia Covarrubias","CONTACT","858-246-2198","ycovarrubias@health.ucsd.edu",{"name":54,"role":50,"phone":10,"phoneExt":10,"email":55},"Gage Tanzman","g1tanzman@health.ucsd.edu",[57],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"University of California San Diego","RECRUITING","La Jolla","California","92037","United States",{"type":65,"coordinates":66},"Point",[67,68],-117.2742,32.84727,{"lat":68,"lon":67},[71,73,74],{"name":49,"role":50,"phone":72,"phoneExt":10,"email":52},"858-246-2193",{"name":54,"role":50,"phone":10,"phoneExt":10,"email":55},{"name":45,"role":46,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Claude Sirlin","Professor of Radiology",[79,82],{"name":80,"class":81},"Livivos, Inc.","UNKNOWN",{"name":83,"class":84},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100632830",false,"NCT07518784","Accurate Point of Care Liver Disease Diagnostics (Phase 2)","Accurate Point of Care Liver Disease Diagnostics","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Known or clinically suspected MASLD\n* BMI greater than 27 kg\u002Fm\\^2 and less than 45 kg\u002Fm\\^2 at the time of referral\n* Ability to lie on LiverScope® device table for about 60 minutes\n* Ability to hold breath repeatedly for about 20 seconds during MR and LiverScope® exams\n* Willing and able to undergo all study procedures\n\nExclusion Criteria:\n\n* UCSD study personnel or Livivos study personne\n* Contraindications to MR\n* Potential participant states that she knows that she is pregnant, thinks she may be pregnant, or states that she is trying to become pregnant.\n* Known chronic liver disease other than MASLD","ALL","18 Years",{"count":94,"type":95},26,"ESTIMATED","OBSERVATIONAL","This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, including advanced conventional liver MR exams. MR exams are common exams used to monitor MASLD (also known as NAFLD). Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use.\n\nIn this second phase of the study, we took what we learned in the first phase to optimize the LiverScope® device and are now testing to see how LiverScope® measurements compare to MR after these optimizations.\n\nStudy participants will be asked to complete a one-time visit which includes:\n\n* LiverScope exam\n* MR exam\n* FibroScan exam (optional)\n* Blood draw\n* Completion of study questionnaires",[99,100,101,102],"MASLD","MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)","NAFLD","NAFLD (Nonalcoholic Fatty Liver Disease)","2026-04-01",{"date":105,"type":106},"2026-04-09","ACTUAL",{"date":108,"type":95},"2026-04-08",{"date":110,"type":95},"2026-06-30",{"name":5,"class":6},1]